Tamsulosin Hydrochloride Capsule
Product Images NDC 50090-1846

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 50090-1846). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500901846)

Tamsulosin Hydrochloride 0.4 mg capsules packaging label from A-S Medication Solutions. The label shows the product NDC 50090-1846-0, batch lot number 100 WK, storage instructions to keep at 68 to 77 degrees Fahrenheit and avoid excessive moisture, and a package count of 30 capsules.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph depicting mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours following a single 0.4 mg oral dose under fasted and fed conditions. The y-axis shows plasma concentration in ng/mL, and the x-axis shows time in hours. The graph compares concentration profiles between fasted (dashed line) and fed (solid line) states in eight subjects.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph showing the mean change from baseline in total AUA symptom score over 13 weeks of treatment, comparing three groups: 0.8 mg dose, 0.4 mg dose, and placebo. The y-axis represents mean change, and the x-axis shows treatment duration in weeks. Both doses show greater symptom score reductions than placebo over time.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean change over 13 weeks of treatment, including a last observation carried forward (LOCF) point. The x-axis represents duration of treatment in weeks, and the y-axis represents mean change. The graph compares three treatments: 0.8 mg and 0.4 mg doses, and placebo. Data points for each treatment show progressive decreases in symptom scores, with 0.8 mg and 0.4 mg doses showing greater reduction than placebo.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing the mean change in urine flow rate over a 13-week treatment period plus follow-up (LOCF). The graph compares treatment groups receiving 0.8 mg and 0.4 mg doses versus placebo, with mean changes plotted on the vertical axis and treatment duration in weeks on the horizontal axis. Sample sizes at each time point are noted below the x-axis.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing data over a 13-week treatment period plus a last observation carried forward (LOCF). The x-axis represents duration of treatment in weeks, and the y-axis shows mean change in peak urine flow rate in mL/sec. The graph compares treatment groups: 0.8 mg, 0.4 mg, and placebo, with mean increases plotted for each time point and distinct line styles and markers for each group.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure diagram depicting the molecular structure of Tamsulosin Hydrochloride, consistent with its active ingredient composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.